TCF4 and breast cancer: Taken together, the ligand- and pathway-specific cell-free and cell-based assays, as well as in silico molecular docking results, demonstrated that BC-23 is a new inhibitor of β-catenin/Tcf4 that specifically targets the β-catenin/Tcf4 interaction and inhibits their transcriptional activity [38].